Fully Human Anti-PD-L1 Antibodies for High-Affinity Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapies targeting the PD-1 pathway for cancer treatment are not fully satisfactory, necessitating the development of novel anti-PD-L1 antibodies with improved binding affinity and specificity to enhance therapeutic efficacy.
Innovation Solution
Development of fully human monoclonal anti-PD-L1 antibodies with specific binding to human PD-L1 at Kd values of ≤10−9 M and reduced effector function, inhibiting PD-L1 receptor binding, and promoting immune response through IL-2 and IFNγ production, T cell proliferation, and reversing T reg's suppressive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-PD-1 therapies are used, then immune response is enhanced, but binding affinity and therapeutic efficacy are not fully satisfactory
Solution Approach 1:
The patent applies parameter changes by optimizing the antibody structure to achieve superior binding affinity (Kd ≤ 10^-9 M) and enhanced therapeutic efficacy. The fully human monoclonal antibodies are engineered with specific variable regions that optimize binding parameters to PD-L1, resolving the contradiction between satisfactory therapy and insufficient binding affinity.
2Reliability
If antibody binding affinity to PD-L1 is increased, then immune response inhibition is enhanced, but off-target effects may increase
Solution Approach 1:
The patent applies local quality by designing antibodies with highly specific binding characteristics localized to the PD-L1 target. The fully human monoclonal antibodies are engineered with precise epitope recognition capabilities that concentrate binding specificity on PD-L1 while minimizing interactions with off-target molecules, thus resolving the contradiction between enhanced inhibition and potential off-target effects.
3Object-affected harmful factors
If effector function is reduced, then safety profile is improved, but immune response activation may be diminished
Solution Approach 1:
The patent applies parameter changes by precisely tuning the effector function parameters of the antibodies. The fully human monoclonal antibodies are engineered with optimized Fc regions that balance safety and efficacy - reducing harmful effector functions like ADCC and CDC while preserving sufficient immune response activation through PD-L1 blockade, thus resolving the contradiction between safety profile and immune response activation.
Data Source
AI summary
The present disclosure provides monoclonal antibodies against protein programmed cell death 1 ligand (PD-L1), which can block the binding of PD-L1 to PD-1, and therefore block the inhibitory function of PD-Li on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.